PharmaDepth

Asset

Abemaciclib

Eli Lilly and Company Common Stock

Revenue

PeriodRevenue
Q2 2026$1.5B
Q1 2026$1.3B
Q4 2025$1.6B
Q3 2025$1.5B
Q2 2025$1.5B
Q1 2025$1.2B
Q4 2024$1.6B
Q3 2024$1.4B
Q2 2024$1.3B
Q1 2024$1.1B
Q3 2023$1.0B
Q2 2023$926.8M
Q1 2023$750.9M
Q4 2022$807.9M
Q3 2022$617.7M

Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.

Clinical trials (56)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT05999994phase2recruiting2020-01-222027-05-01Eli Lilly and CompanyA Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT02441946phase2completed2015-08-012016-08-16Eli Lilly and CompanyA Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT01394016phase1completed2009-12-072014-05-29Eli Lilly and CompanyA Phase 1 Study of LY2835219 In Participants With Advanced Cancer
NCT06413706phase2active_not_recruiting2024-10-252027-02-01Eli Lilly and CompanyA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT02745769phase1completed2016-10-212018-11-05Eli Lilly and CompanyA Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

FDA applications (2)

ApplicationApprovedTypeApplicant
NDA 2087162017-09-28NDAELI LILLY AND CO
NDA 208855—NDAELI LILLY AND CO

Marketed products (8)

  • VERZENIO
  • VERZENIO
  • VERZENIO
  • VERZENIO
  • VERZENIO
  • VERZENIO
  • VERZENIO
  • VERZENIO